Attitudes and beliefs among Georgia addiction treatment staff about medication for opioid use disorder in adolescents, young adults, and adults: a multi-mixed methods study

References

• Chatterjee A, Larochelle MR, Xuan Z, Wang N, Bernson D, Silverstein M, Hadland SE, Land T, Samet JH, Walley AY, et al. Non-Fatal opioid-related overdoses among adolescents in Massachusetts 2012-2014. Drug Alcohol Depend. 2019; 194:28–31. doi:https://doi.org/10.1016/j.drugalcdep.2018.09.020.
   PubMed Web of Science ®Google Scholar
• Yule AM, Lyons RM, Wilens TE. Opioid use disorders in adolescents—Updates in assessment and management. Curr Pediatr Rep. 2018; 6:99–106. doi:https://doi.org/10.1007/s40124-018-0161-z.
   PubMedGoogle Scholar
• Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2019 national survey on drug use and health. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration [Internet]; 2020 [accessed 2020 Nov 4]; Available from: https://store.samhsa.gov/product/key-substance-use-and-mental-health-indicators-in-the-united-states-results-from-the-2019-national-survey-on-Drug-Use-and-Health/PEP20-07-01-001.
   Google Scholar
• Woodcock EA, Lundahl LH, Stoltman JJK, Greenwald MK. Progression to regular heroin use: examination of patterns, predictors, and consequences. Addict Behav. 2015; 45:287–93. doi:https://doi.org/10.1016/j.addbeh.2015.02.014.
   PubMed Web of Science ®Google Scholar
• Gaither JR, Shabanova V, Leventhal JM. US national trends in pediatric deaths from prescription and illicit opioids, 1999-2016. JAMA Network Open. 2018; 1:e186558. doi: https://doi.org/10.1001/jamanetworkopen.2018.6558.
   PubMed Web of Science ®Google Scholar
• Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019; 393:1760–72. doi:https://doi.org/10.1016/S0140-6736(18)33078-2.
   PubMed Web of Science ®Google Scholar
• Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, Marshall BDL, Tyndall M, Walsh SL. Opioid use disorder. Nat Rev Dis Primers. 2020; 6:3. doi:https://doi.org/10.1038/s41572-019-0137-5.
   PubMed Web of Science ®Google Scholar
• Indivior Inc. Suboxone (buprenorphine and naloxone): highlights of prescribing information; 2016. Retrieved from http://www.suboxone.com/content/pdfs/prescribing-information.pdf.
   Google Scholar
• Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, Brooklyn J. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005; 62:1157–64. doi:https://doi.org/10.1001/archpsyc.62.10.1157.
   PubMed Web of Science ®Google Scholar
• Marsch LA, Moore SK, Borodovsky JT, Solhkhah R, Badger GJ, Semino S, Jarrett K, Condon KD, Rossettie K, Vincent P, et al. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction. 2016; 111:1406–15. doi:https://doi.org/10.1111/add.13363.
   PubMed Web of Science ®Google Scholar
• Bell J, Mutch C. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review. Drug Alcohol Rev. 2006; 25:167–71. doi:https://doi.org/10.1080/09595230500537670.
   PubMed Web of Science ®Google Scholar
• Kellogg S, Melia D, Khuri E, Lin A, Ho A, Kreek MJ.Adolescent and young adult heroin patients: drug use and success in methadone maintenance treatment. J Addict Dis. 2006; 25:15–25. doi:https://doi.org/10.1300/J069v25n03_03.
   PubMed Web of Science ®Google Scholar
• Camenga DR, Colon-Rivera HA, Muvvala SB. Medications for maintenance treatment of opioid use disorder in adolescents: a narrative review and assessment of clinical benefits and potential risks. J Stud Alcohol Drugs. 2019; 80:393–402. doi: https://doi.org/10.15288/jsad.2019.80.393.
   PubMed Web of Science ®Google Scholar
• Fishman MJ, Winstanley EL, Curran E, Garrett S, Subramaniam G.Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility. Addiction. 2010;105:1669–76. doi:https://doi.org/10.1111/j.1360-0443.2010.03015.x.
   PubMed Web of Science ®Google Scholar
• Mitchell SG, Monico LB, Gryczynski J, Fishman MJ, O’-Grady KE, Schwartz RP. Extended-Release naltrexone for youth with opioid use disorder. J Subst Abuse Treat. 2021; 130:108407. doi:https://doi.org/10.1016/j.jsat.2021.108407.
   PubMed Web of Science ®Google Scholar
• Committee on Substance Use And Prevention. Medication-Assisted treatment of adolescents with opioid use disorders. Pediatrics. 2016; 138:e20161893. doi:https://doi.org/10.1542/peds.2016-1893.
   PubMed Web of Science ®Google Scholar
• Hadland SE, Bagley SM, Rodean J, Silverstein M, Levy S, Larochelle MR, Samet JH, Zima BT. Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder. JAMA Pediatr. 2018; 172:1029–37. doi:https://doi.org/10.1001/jamapediatrics.2018.2143.
   PubMed Web of Science ®Google Scholar
• Welsh JW, Mataczynski MJ, Nguyen MD, McHugh RK. A review of behavioral therapies in adolescents with opioid use disorder. Harv Rev Psychiatry. 2020; 28:305–15. doi:https://doi.org/10.1097/HRP.0000000000000272.
   PubMed Web of Science ®Google Scholar
• Alinsky RH, Zima BT, Rodean J, Matson PA, Larochelle MR, Adger H, Bagley SM, Hadland SE. Receipt of addiction treatment after opioid overdose among medicaid-enrolled adolescents and young adults. JAMA Pediatr. 2020; 174:e195183. doi:https://doi.org/10.1001/jamapediatrics.2019.5183.
   PubMed Web of Science ®Google Scholar
• Welsh JW, Dennis ML, Funk R, Mataczynski MJ, and Godley MD. Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults. J Subst Abuse Treat 2021; 132:108584.
   PubMed Web of Science ®Google Scholar
• Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014. JAMA Pediatr. 2017; 171:747–55. doi:https://doi.org/10.1001/jamapediatrics.2017.0745.
   PubMed Web of Science ®Google Scholar
• Bagley SM, Hadland SE, Carney BL, Saitz R. Addressing stigma in medication treatment of adolescents with opioid use disorder. J Addict Med. 2017; 11:415–16. doi:https://doi.org/10.1097/ADM.0000000000000348.
   PubMed Web of Science ®Google Scholar
• Hadland SE, Park TW, Bagley SM. Stigma associated with medication treatment for young adults with opioid use disorder: a case series. Addict Sci Clin Pract. 2018; 13:15. doi:https://doi.org/10.1186/s13722-018-0116-2.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Treatment episode data set - discharge (TEDS-D): 2019; 2021. Available from: https://www.samhsa.gov/data/data-we-collect/teds-treatment-episode-data-set.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. National survey on drug use and health: 2-year RDAS (2018 to 2019),//rdas.Samhsa.gov/#/survey/nsduh-2018-2019-RD02YR/crosstab/?weight=DASWT_1&run_chisq=false&results_received=true [Internet]. Substance Abuse and Mental Health Services Administration; 2019. Available from: https://rdas.samhsa.gov/#/survey/NSDUH-2018-2019-RD02YR.
   Google Scholar
• Boyatzis RE. Transforming qualitative information: thematic analysis and code development. Vol. xvi. Thousand Oaks (CA): Sage Publications, Inc; 1998p 184 p. (Transforming qualitative information: Thematic analysis and code development).
   Google Scholar
• Miles MB, Huberman MA. Qualitative data analysis: A methods sourcebook. Los Angeles (CA): Sage Publications; 2020.
   Google Scholar
• Andraka-Christou B, Gabriel M, Madeira J, Silverman RD. Court personnel attitudes towards medication-assisted treatment: A state-wide survey. J Subst Abuse Treat. 2019; 104:72–82. doi:https://doi.org/10.1016/j.jsat.2019.06.011.
   PubMed Web of Science ®Google Scholar
• Matusow H, Dickman SL, Rich JD, Fong C, Dumont DM, Hardin C, Marlowe D, Rosenblum A. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013; 44:473–80. doi:https://doi.org/10.1016/j.jsat.2012.10.004.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Rich JD. Barriers to medications for addiction treatment: how stigma kills. Subst Use Misuse. 2018; 53:330–33. doi: https://doi.org/10.1080/10826084.2017.1363238.
   PubMed Web of Science ®Google Scholar
• Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon ME. Medication-Assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014; 65:158–70. doi:https://doi.org/10.1176/appi.ps.201300256.
   PubMed Web of Science ®Google Scholar
• Ma J, Bao Y-P, Wang R-J, M-F S, Liu M-X, Li J-Q, Degenhardt L, Farrell M, Blow FC, and Ilgen M, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2019; 24(12):1868–1883.
   PubMed Web of Science ®Google Scholar
• Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, Patkar A, Publicker M, McCain K, Potter JS, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth. Jama. 2008; 300:2003–11. doi:https://doi.org/10.1001/jama.2008.574.
   PubMed Web of Science ®Google Scholar
• Bergman BG, Ashford RD, Kelly JF. Attitudes toward opioid use disorder medications: results from a U.S. national study of individuals who resolved a substance use problem. Exp Clin Psychopharmacol. 2020; 28:449–61. doi: https://doi.org/10.1037/pha0000325.
   PubMed Web of Science ®Google Scholar
• Uebelacker LA, Bailey G, Herman D, Anderson B, Stein M. Patients’ beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. J Subst Abuse Treat. 2016; 66:48–53. doi:https://doi.org/10.1016/j.jsat.2016.02.009.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open. 2020; 3:e1920622. doi:https://doi.org/10.1001/jamanetworkopen.2019.20622.
   PubMed Web of Science ®Google Scholar
• Lee JD, Nunes EV, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018; 391:309–18. doi:https://doi.org/10.1016/S0140-6736(17)32812-X.
   PubMed Web of Science ®Google Scholar
• Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2018; 67:1419–27. doi: https://doi.org/10.15585/mmwr.mm675152e1.
   PubMed Web of Science ®Google Scholar
• Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The burden of opioid-related mortality in the United States. JAMA Network Open. 2018; 1:e180217. doi: https://doi.org/10.1001/jamanetworkopen.2018.0217.
   PubMed Web of Science ®Google Scholar